Microsoft (NASDAQ:MSFT) is collaborating with Denmark’s Novo Nordisk (NASDAQ:NVO) to bring together computational services, cloud, and AI and Novo’s expertise in drug discovery, development, and data science.
The move is aimed at accelerating Novo’s R&D and expanding its AI capabilities. The AI models resulting from this partnership will be used in a number of use cases.
The first two of these use cases- automated summarization and analysis of information and developing models to predict the risk of developing atherosclerosis (a cardiovascular disease)- are already in execution.
Additionally, the platform approach undertaken will enable the collaboration to initiate new projects and use cases on a continuous basis.
Read full Disclosure